Despite magrolimab’s latest flop, efforts to target CD47 continue.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.

The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.

Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.

Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.